Novo Nordisk CEO tells investors to expect weight-loss drug pricing to go down before it comes back up

Recently-appointed CEO Mike Doustdar has repeatedly reset expectations since his arrival. Pricing and regulatory pressure is fierce and pessimistic revenue guidance has seen the stock clobbered 17% in Copenhagen.

Previous Article

Second Iranian Diplomat In Europe Defects, Seeks Asylum, Amid US Pressure Campaign 

Next Article

What this famed short seller is waiting for before betting against AI stocks

Write a Comment

Leave a Comment

Your email address will not be published. Required fields are marked *

− 1 = 5
Powered by MathCaptcha

Subscribe to our Newsletter

Subscribe to our email newsletter to get the latest posts delivered right to your email.
Pure inspiration, zero spam ✨